Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

BACKGROUND: Induction therapy is crucial in kidney transplantation and constitutes an important cornerstone for long-term allograft survival. Alemtuzumab is a depleting CD52-specific antibody with T- and B-cell activity, leading to prolonged lymphocyte depletion for up to 12 months, with profound im...

Descripción completa

Detalles Bibliográficos
Autores principales: Guthoff, Martina, Berger, Kilian, Althaus, Karina, Mühlbacher, Thomas, Bakchoul, Tamam, Steurer, Wolfgang, Nadalin, Silvio, Königsrainer, Alfred, Heyne, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218828/
https://www.ncbi.nlm.nih.gov/pubmed/32404066
http://dx.doi.org/10.1186/s12882-020-01767-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218828/
https://www.ncbi.nlm.nih.gov/pubmed/32404066
http://dx.doi.org/10.1186/s12882-020-01767-z

Ejemplares similares